Edwards Lifesciences Corporation (EW) saw its stock price surge 5.69% in a 24-hour period on Thursday, following the release of its impressive second-quarter 2025 financial results and an upward revision of its full-year guidance. The medical technology company's performance exceeded analyst expectations, driving investor optimism and fueling the significant stock price increase.

The company reported a robust 11.9% increase in Q2 sales, reaching $1.53 billion, surpassing the analysts' estimate of $1.49 billion. Adjusted earnings per share (EPS) came in at $0.67, beating the consensus estimate of $0.62. Edwards Lifesciences' strong performance was driven by growth across its product lines, with Transcatheter Aortic Valve Replacement (TAVR) sales rising 8.9% to $1.13 billion, and Transcatheter Mitral and Tricuspid Therapies (TMTT) sales reaching $134.5 million.

In light of these strong results, Edwards Lifesciences raised its full-year 2025 guidance. The company now expects total sales growth of 9% to 10%, projecting revenues between $5.9 billion and $6.1 billion. Additionally, the company adjusted its underlying growth rate guidance for TAVR to 6% to 7%. The positive outlook, coupled with the Q2 earnings beat, appears to have fueled investor optimism, leading to the significant stock price increase. However, investors seemed to shrug off news of an FDA recall of Edwards Lifesciences' Arterial Cannula due to the risk of wire exposure, as the overall strength of the company's business outlook overshadowed this regulatory concern.